NO20083642L - Dibenzylaminderivater som CETP-inhibitorer - Google Patents
Dibenzylaminderivater som CETP-inhibitorerInfo
- Publication number
- NO20083642L NO20083642L NO20083642A NO20083642A NO20083642L NO 20083642 L NO20083642 L NO 20083642L NO 20083642 A NO20083642 A NO 20083642A NO 20083642 A NO20083642 A NO 20083642A NO 20083642 L NO20083642 L NO 20083642L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- derivatives
- dibenzylamine
- cetp inhibitors
- triglycerides
- Prior art date
Links
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 2
- 238000008214 LDL Cholesterol Methods 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 150000003626 triacylglycerols Chemical class 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78148806P | 2006-03-10 | 2006-03-10 | |
| US11/619,299 US8383660B2 (en) | 2006-03-10 | 2007-01-03 | Dibenzyl amine compounds and derivatives |
| PCT/IB2007/000524 WO2007105049A1 (fr) | 2006-03-10 | 2007-02-28 | Dérivés de dibenzylamine en tant qu'inhibiteurs de cetp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20083642L true NO20083642L (no) | 2008-09-29 |
Family
ID=38085975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20083642A NO20083642L (no) | 2006-03-10 | 2008-08-22 | Dibenzylaminderivater som CETP-inhibitorer |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8383660B2 (fr) |
| EP (1) | EP1994015B1 (fr) |
| JP (1) | JP4959731B2 (fr) |
| KR (1) | KR101059274B1 (fr) |
| AP (1) | AP2008004603A0 (fr) |
| AR (1) | AR059802A1 (fr) |
| AU (1) | AU2007226260B2 (fr) |
| BR (1) | BRPI0708753A2 (fr) |
| CA (2) | CA2717242A1 (fr) |
| CR (1) | CR10265A (fr) |
| DK (1) | DK1994015T3 (fr) |
| DO (1) | DOP2007000044A (fr) |
| ES (1) | ES2410859T3 (fr) |
| IL (1) | IL193572A (fr) |
| MA (1) | MA30272B1 (fr) |
| MX (1) | MX2008011045A (fr) |
| NL (1) | NL2000527C2 (fr) |
| NO (1) | NO20083642L (fr) |
| PE (1) | PE20071022A1 (fr) |
| RS (1) | RS20080409A (fr) |
| TW (1) | TW200736235A (fr) |
| UY (1) | UY30197A1 (fr) |
| WO (1) | WO2007105049A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009011998A (es) * | 2007-05-10 | 2009-11-19 | Pfizer Ltd | Derivados de azetidina y su uso como antagonistas de prostaglandina e2. |
| WO2010064146A2 (fr) | 2008-12-02 | 2010-06-10 | Chiralgen, Ltd. | Procédé pour la synthèse d’acides nucléiques modifiés par des atomes de phosphore |
| CA2767253A1 (fr) | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Nouveaux precurseurs d'acide nucleique et leurs methodes d'utilisation |
| CN102241667B (zh) * | 2010-05-14 | 2013-10-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 1-[(4-羟基哌啶-4基)甲基]吡啶-2(1h)-酮衍生物及其制备方法和用途 |
| CA2809958A1 (fr) | 2010-08-31 | 2012-03-08 | Snu R & Db Foundation | Utilisation de la reprogrammation ftale d'un agoniste des ppar ? |
| WO2012039448A1 (fr) * | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | Groupe auxiliaire asymétrique |
| TWI627167B (zh) | 2011-07-08 | 2018-06-21 | 諾華公司 | 用於高三酸甘油酯個體治療動脈粥狀硬化之方法 |
| CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| CA2879066C (fr) | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Adjuvant d'acide nucleique chiral |
| WO2014010250A1 (fr) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Groupe auxiliaire asymétrique |
| JP6453212B2 (ja) | 2012-07-13 | 2019-01-16 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | キラル制御 |
| CN103351354B (zh) * | 2013-06-09 | 2015-08-12 | 西安近代化学研究所 | 1-甲基-5-氨基四唑合成方法 |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| WO2015108047A1 (fr) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité |
| JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| KR20230152178A (ko) | 2014-01-16 | 2023-11-02 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
| WO2017030367A1 (fr) * | 2015-08-17 | 2017-02-23 | 인제대학교 산학협력단 | Nouveau composé d'isonitramine et composition le contenant pour prévenir ou traiter des maladies métaboliques |
| US20180244624A1 (en) | 2015-08-17 | 2018-08-30 | Inje University Industry-Academic Cooperation Foundation | Novel isonitramine compound and composition containing same for preventing or treating metabolic diseases |
| WO2025125486A1 (fr) | 2023-12-14 | 2025-06-19 | Syngenta Crop Protection Ag | Procédé de préparation de dérivés de pipéridinyl 1,2,4-oxadiazole |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2161938A (en) | 1934-07-31 | 1939-06-13 | Soc Of Chemical Ind | Imidazolines |
| US2970082A (en) | 1958-10-07 | 1961-01-31 | Walker Lab Inc | Aluminum nicotinate compositions for hypercholesteremia |
| DE1518133B1 (de) | 1961-10-05 | 1970-08-20 | Farmaceutici Italia | Verfahren zur Herstellung eines neuen hypotensiv wirkenden Hendekapeptids |
| US3228943A (en) | 1962-06-11 | 1966-01-11 | Lumilysergol derivatives | |
| US3338899A (en) | 1962-07-09 | 1967-08-29 | Aron Samuel | 3-phenyl-5-amino-1, 2, 4-oxadiazole compounds |
| US3238215A (en) | 1963-10-17 | 1966-03-01 | Sterling Drug Inc | 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines |
| NL127065C (fr) | 1964-04-22 | |||
| FR1460571A (fr) | 1965-06-10 | 1966-03-04 | Innothera Lab Sa | Composés thiényl acétiques et leur préparation |
| FR6087M (fr) | 1967-01-10 | 1968-06-04 | ||
| US3511836A (en) | 1967-12-13 | 1970-05-12 | Pfizer & Co C | 2,4,6,7-tetra substituted quinazolines |
| BE729170A (fr) | 1968-03-02 | 1969-08-01 | ||
| GB1218591A (en) | 1968-04-03 | 1971-01-06 | Delalande Sa | Derivatives of n-(3,4,5-trimethoxy cennamoyl) piperazine and their process of preparation |
| CH507249A (de) | 1968-05-31 | 1971-05-15 | Sandoz Ag | Verfahren zur Herstellung von 2-Brom-a-ergokryptin |
| FR2092133B1 (fr) | 1970-05-06 | 1974-03-22 | Orsymonde | |
| GB1435139A (en) | 1972-08-17 | 1976-05-12 | Sumitomo Chemical Co | Thiazole derivatives |
| US4146643A (en) | 1973-12-18 | 1979-03-27 | Sandoz Ltd. | Increasing vigilance or treating cerebral insufficiency with substituted vincamines |
| NL175059C (nl) | 1974-02-23 | Boehringer Mannheim Gmbh | Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten. | |
| DE2733747C2 (de) | 1977-07-27 | 1979-09-27 | Hoechst Ag, 6000 Frankfurt | Verfahren zur Herstellung von 2,2 Dichlorhydrazobenzol |
| US4188390A (en) | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
| IT1094076B (it) | 1978-04-18 | 1985-07-26 | Acraf | Cicloalchiltriazoli |
| JPS56110665A (en) | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Sulfamoyl-substituted phenetylamine derivative and its preparation |
| US5061798A (en) | 1985-01-18 | 1991-10-29 | Smith Kline & French Laboratories, Ltd. | Benzyl pyridyl and pyridazinyl compounds |
| GB8501372D0 (en) | 1985-01-18 | 1985-02-20 | Smith Kline French Lab | Chemical compounds |
| GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| US5284971A (en) | 1992-07-16 | 1994-02-08 | Syntex (U.S.A.) Inc. | 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents |
| ATE159515T1 (de) | 1992-07-21 | 1997-11-15 | Ciba Geigy Ag | Oxamidsäure-derivate als hypocholesterämische mittel |
| DE4435477A1 (de) | 1994-10-04 | 1996-04-11 | Bayer Ag | Cycloalkano-indol- und -azaindol-derivate |
| US5521186A (en) | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
| DE69519995T2 (de) | 1994-10-27 | 2001-08-23 | Janssen Pharmaceutica Nv | Apolipoprotein-b syntheseinhibitoren |
| EP0832069B1 (fr) | 1995-06-07 | 2003-03-05 | Pfizer Inc. | DERIVES DE BIPHENYL-2-ACIDE CARBOXYLIQUE-TETRAHYDRO-ISOQUINOLEINE-6-YL AMIDES, PREPARATION DE CES AMIDES ET UTILISATION EN TANT QU'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE TRIGLYCERIDE MICROSOMAL ET/OU DE LA SECRETION D'APOLIPOPROTEINES B (Apo B) |
| EA001539B1 (ru) | 1996-11-27 | 2001-04-23 | Пфайзер Инк. | Амиды, ингибирующие секрецию аполипопротеина в (аро в) и/или микросомного протеина переноса триглицеридов (мтр) |
| JP2894445B2 (ja) * | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Cetp活性阻害剤として有効な化合物 |
| HRP20031051B1 (en) | 2001-06-28 | 2012-01-31 | Pfizer Products Inc. | Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion |
| JP2003221376A (ja) | 2001-11-21 | 2003-08-05 | Japan Tobacco Inc | Cetp活性阻害剤 |
| US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| SI1533292T1 (sl) | 2002-08-30 | 2007-08-31 | Japan Tobacco Inc | Dibenzilaminska spojina in njena medicinska uporaba |
| US6653334B1 (en) * | 2002-12-27 | 2003-11-25 | Kowa Co., Ltd. | Benzoxazole compound and pharmaceutical composition containing the same |
| JP4922924B2 (ja) * | 2004-04-13 | 2012-04-25 | メルク・シャープ・エンド・ドーム・コーポレイション | Cetp阻害薬 |
| DOP2005000123A (es) * | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| US20090239865A1 (en) | 2004-11-23 | 2009-09-24 | George Chang | Dibenzyl amine compounds and derivatives |
| MX2007007919A (es) * | 2004-12-31 | 2008-01-22 | Reddy Us Therapeutics Inc | Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp). |
| JP2009513573A (ja) * | 2005-09-30 | 2009-04-02 | メルク エンド カムパニー インコーポレーテッド | コレステリルエステル転送蛋白阻害剤 |
| US7919506B2 (en) * | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
-
2007
- 2007-01-03 US US11/619,299 patent/US8383660B2/en not_active Expired - Fee Related
- 2007-02-28 ES ES07705669T patent/ES2410859T3/es active Active
- 2007-02-28 KR KR1020087022081A patent/KR101059274B1/ko not_active Expired - Fee Related
- 2007-02-28 WO PCT/IB2007/000524 patent/WO2007105049A1/fr not_active Ceased
- 2007-02-28 AP AP2008004603A patent/AP2008004603A0/xx unknown
- 2007-02-28 CA CA2717242A patent/CA2717242A1/fr not_active Abandoned
- 2007-02-28 MX MX2008011045A patent/MX2008011045A/es active IP Right Grant
- 2007-02-28 AU AU2007226260A patent/AU2007226260B2/en not_active Ceased
- 2007-02-28 BR BRPI0708753-5A patent/BRPI0708753A2/pt not_active Application Discontinuation
- 2007-02-28 RS RSP-2008/0409A patent/RS20080409A/sr unknown
- 2007-02-28 JP JP2008558923A patent/JP4959731B2/ja not_active Expired - Fee Related
- 2007-02-28 DK DK07705669.5T patent/DK1994015T3/da active
- 2007-02-28 EP EP07705669.5A patent/EP1994015B1/fr active Active
- 2007-02-28 CA CA2645291A patent/CA2645291C/fr not_active Expired - Fee Related
- 2007-03-07 NL NL2000527A patent/NL2000527C2/nl not_active IP Right Cessation
- 2007-03-07 DO DO2007000044A patent/DOP2007000044A/es unknown
- 2007-03-08 UY UY30197A patent/UY30197A1/es not_active Application Discontinuation
- 2007-03-09 PE PE2007000259A patent/PE20071022A1/es not_active Application Discontinuation
- 2007-03-09 AR ARP070100979A patent/AR059802A1/es unknown
- 2007-03-09 TW TW096108178A patent/TW200736235A/zh unknown
-
2008
- 2008-08-20 IL IL193572A patent/IL193572A/en not_active IP Right Cessation
- 2008-08-22 NO NO20083642A patent/NO20083642L/no not_active Application Discontinuation
- 2008-08-29 CR CR10265A patent/CR10265A/es not_active Application Discontinuation
- 2008-09-10 MA MA31226A patent/MA30272B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1994015A1 (fr) | 2008-11-26 |
| ES2410859T3 (es) | 2013-07-03 |
| KR20080093156A (ko) | 2008-10-20 |
| PE20071022A1 (es) | 2007-10-06 |
| AU2007226260A1 (en) | 2007-09-20 |
| NL2000527C2 (nl) | 2008-02-06 |
| NL2000527A1 (nl) | 2007-09-11 |
| AP2008004603A0 (en) | 2008-10-31 |
| CA2717242A1 (fr) | 2007-09-20 |
| AU2007226260B2 (en) | 2012-02-09 |
| EP1994015B1 (fr) | 2013-04-24 |
| KR101059274B1 (ko) | 2011-08-24 |
| CA2645291A1 (fr) | 2007-09-20 |
| TW200736235A (en) | 2007-10-01 |
| JP2009529573A (ja) | 2009-08-20 |
| MX2008011045A (es) | 2008-09-08 |
| JP4959731B2 (ja) | 2012-06-27 |
| US8383660B2 (en) | 2013-02-26 |
| DOP2007000044A (es) | 2007-09-15 |
| US20070213314A1 (en) | 2007-09-13 |
| IL193572A (en) | 2013-02-28 |
| BRPI0708753A2 (pt) | 2011-06-28 |
| WO2007105049A1 (fr) | 2007-09-20 |
| RS20080409A (sr) | 2009-07-15 |
| CA2645291C (fr) | 2011-06-28 |
| MA30272B1 (fr) | 2009-03-02 |
| DK1994015T3 (da) | 2013-06-24 |
| IL193572A0 (en) | 2009-05-04 |
| CR10265A (es) | 2008-09-23 |
| UY30197A1 (es) | 2007-10-31 |
| AR059802A1 (es) | 2008-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20083642L (no) | Dibenzylaminderivater som CETP-inhibitorer | |
| NO20073025L (no) | Dibenzylaminforbindelser og derivater | |
| NO20084931L (no) | Farmasoytiske sammensetninger | |
| NO20070933L (no) | Indazoler anvendbare i behandling av kardiovaskulaere sykdommer | |
| NO20083568L (no) | Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser | |
| NO20083561L (no) | Forbindelser for behandling av inflammatoriske forstyrrelser | |
| WO2010079431A3 (fr) | Composés pour la prévention et le traitement de maladies cardiovasculaires | |
| NO20082000L (no) | Pyrimidinamidforbindelser som PGDS-inhibitorer | |
| EA201290389A1 (ru) | Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени | |
| NO20081454L (no) | Met-kinaseinhibitorer | |
| DK2358717T3 (da) | Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes | |
| UA102574C2 (ru) | 1-фенил-2-пиридинилалкил-спиртовые производные как ингибиторы фосфодиэстеразы | |
| NO20083572L (no) | Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer | |
| NO20084411L (no) | Tetrahydro-pyrimidoazepiner som modulatorer av TRPVI | |
| NZ594854A (en) | Low-molecular polysulfated hyaluronic acid derivative and medicine containing same | |
| EA200970090A1 (ru) | Модуляторы метаболизма и лечение связанных с ним расстройств | |
| NO20083690L (no) | Hydantoin baserte kinase-inhibitorer | |
| WO2008075172A3 (fr) | Dérivés de nicotinamide | |
| NO20073849L (no) | Indolderivater for behandling av virale infeksjoner | |
| NO20082124L (no) | Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom | |
| WO2011056985A3 (fr) | Composés hétérocycliques substitués | |
| NO20076197L (no) | Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander | |
| MD20140044A2 (ro) | 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare | |
| NO20085212L (no) | Nye pyridinanaloger | |
| NO20052921L (no) | Fenylsubstituerte piperidinforbindelser for anvendelse som PPAR aktivatorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |